Akums Drugs and Pharmaceuticals Limited (NSE:AKUMS)
India
· Delayed Price · Currency is INR 517.20
+9.15 (1.80%)
Mar 12, 2025, 9:15 AM IST
NSE:AKUMS Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| Operating Revenue | 40,068 | 41,782 | 36,548 | 36,719 | 27,226 |
| Other Revenue | 34.8 | 34.8 | 23.7 | 33.29 | 35.83 |
| Revenue | 40,103 | 41,817 | 36,572 | 36,752 | 27,262 |
| Revenue Growth (YoY) | -3.40% | 14.34% | -0.49% | 34.81% | - |
| Cost of Revenue | 24,338 | 26,204 | 23,493 | 24,145 | 17,343 |
| Gross Profit | 15,765 | 15,613 | 13,079 | 12,607 | 9,919 |
| Selling, General & Admin | 7,408 | 6,918 | 6,291 | 5,399 | 4,541 |
| Other Operating Expenses | 3,769 | 3,848 | 3,765 | 3,104 | 2,424 |
| Operating Expenses | 12,651 | 12,023 | 11,184 | 9,449 | 7,663 |
| Operating Income | 3,114 | 3,590 | 1,895 | 3,158 | 2,256 |
| Interest Expense | -420.72 | -502.51 | -459.73 | -163.38 | -63.88 |
| Interest & Investment Income | 119.99 | 119.99 | 78.8 | 46.31 | 61.44 |
| Earnings From Equity Investments | - | - | -2.03 | 2.03 | 3.47 |
| Currency Exchange Gain (Loss) | 72.05 | 72.05 | -38.93 | 26.46 | 27.36 |
| Other Non Operating Income (Expenses) | -653.88 | -3,526 | 490.16 | -4,883 | -490.62 |
| EBT Excluding Unusual Items | 2,232 | -246.18 | 1,963 | -1,813 | 1,794 |
| Impairment of Goodwill | - | - | - | -129.77 | -100 |
| Gain (Loss) on Sale of Investments | - | - | - | - | 0.77 |
| Gain (Loss) on Sale of Assets | -3.17 | -3.17 | 45.75 | -20.66 | -4.04 |
| Asset Writedown | -7.23 | -7.23 | -722.64 | 10.55 | - |
| Other Unusual Items | 151.11 | -196.2 | 216.81 | 21 | 32.16 |
| Pretax Income | 2,372 | -452.78 | 1,503 | -1,932 | 1,723 |
| Income Tax Expense | 825.31 | -460.68 | 524.8 | 576.77 | 488.26 |
| Earnings From Continuing Operations | 1,547 | 7.9 | 978.17 | -2,509 | 1,234 |
| Minority Interest in Earnings | -54.64 | -48.25 | -29.62 | -16.62 | -7.3 |
| Net Income | 1,492 | -40.35 | 948.55 | -2,525 | 1,227 |
| Net Income to Common | 1,492 | -40.35 | 948.55 | -2,525 | 1,227 |
| Shares Outstanding (Basic) | 147 | 143 | 143 | 143 | 143 |
| Shares Outstanding (Diluted) | 147 | 143 | 143 | 143 | 143 |
| Shares Change (YoY) | 3.03% | - | - | - | - |
| EPS (Basic) | 10.14 | -0.28 | 6.63 | -17.65 | 8.58 |
| EPS (Diluted) | 10.14 | -0.28 | 6.63 | -17.65 | 8.58 |
| Free Cash Flow | - | 1,869 | -1,522 | -2,257 | 478.04 |
| Free Cash Flow Per Share | - | 13.06 | -10.64 | -15.78 | 3.34 |
| Gross Margin | 39.31% | 37.34% | 35.76% | 34.30% | 36.38% |
| Operating Margin | 7.77% | 8.59% | 5.18% | 8.59% | 8.28% |
| Profit Margin | 3.72% | -0.10% | 2.59% | -6.87% | 4.50% |
| Free Cash Flow Margin | - | 4.47% | -4.16% | -6.14% | 1.75% |
| EBITDA | 4,354 | 4,733 | 2,908 | 4,005 | 2,880 |
| EBITDA Margin | 10.86% | 11.32% | 7.95% | 10.90% | 10.57% |
| D&A For EBITDA | 1,240 | 1,142 | 1,013 | 846.75 | 624.48 |
| EBIT | 3,114 | 3,590 | 1,895 | 3,158 | 2,256 |
| EBIT Margin | 7.77% | 8.59% | 5.18% | 8.59% | 8.28% |
| Effective Tax Rate | 34.79% | - | 34.92% | - | 28.34% |
| Revenue as Reported | 40,516 | 42,122 | 37,009 | 36,945 | 27,438 |
| Advertising Expenses | - | 389.87 | 354.65 | 294.51 | 257.82 |
Source: S&P Capital IQ. Standard template. Financial Sources.